China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
87 hedge funds and large institutions have $1.29B invested in China Biologic Products Holdings, Inc. in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 14 closing their positions.
131% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $13.2M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
1% less funds holding
Funds holding: 88 → 87 (-1)
27% less capital invested
Capital invested by funds: $1.77B → $1.29B (-$486M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCP
Maso Capital Partners
Hong Kong
|
+$36.6M |
| 2 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$24M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$16.2M |
| 4 |
Man Group
London,
United Kingdom
|
+$10.5M |
| 5 |
Goldman Sachs
New York
|
+$8.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$481M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$55.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.3M |
| 4 |
GAM
Greenwoods Asset Management
Grand Cayman,
Cayman Islands
|
-$21.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.4M |
CBPO Hedge Fund Activity: Q4 2019 in Review
87 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2019, worth a combined $1.29B — down 27% from $1.77B a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CBPO and 13 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 29 added.
The largest buyer was Maso Capital Partners, adding an estimated $36.6M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $481M sold.
- 87 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2019, down from 88 in Q3 2019.
- Funds reported $1.29B of China Biologic Products Holdings, Inc. stock for Q4 2019, down 27% quarter-over-quarter.
- 13 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2019 and 14 closed out, a net change of -1 holder.
- The largest China Biologic Products Holdings, Inc. buyer in Q4 2019 was Maso Capital Partners, an estimated $36.6M added.
- The largest China Biologic Products Holdings, Inc. seller in Q4 2019 was Capital Research Global Investors, an estimated $481M sold.
Based on aggregated 13F filings for Q4 2019.